Tumor Disease Screening and NLS Technology with Biophilia Tracker
Tumor Disease Screening and NLS Technology with Biophilia Tracker
Tumor disease screening is an organized measure aimed at detecting disease in individuals who exhibit no clinical symptoms and have no specific reason to seek medical care. Large-scale NLS-based screening initiatives aimed at the early diagnosis of tumors have always had both proponents and opponents. This is because the detection of a tumor during the preclinical stage does not always equate to "early diagnosis" in the strict sense. Currently, any tumor screening program—including those utilizing NLS technology and the Biophilia Tracker —must meet specific fundamental criteria: the disease must be sufficiently prevalent and of significant social importance; the NLS diagnostic method must be capable of detecting the disease at the preclinical stage; there must be a viable treatment for the detected disease; screening should reduce mortality rates associated with the specific disease within the population; and the program must be economically justifiable (i.e., the cost of early diagnosis should be lower than the cost of treating a patient who presents with clinical symptoms).
Today, the effectiveness of tumor disease screening is indisputable. In recent years, significant discussion has focused on various aspects of these programs, specifically:
Age limits and the appropriate timing for initiating and concluding screening procedures, depending on national guidelines;
The potential of the Biophilia Tracker to assess tumors in various anatomical locations;
The current state of primary and specialized diagnostic techniques for tumors.
Other preclinical diagnostic procedures are also rapidly developing, such as early lung cancer detection using virtual multivariable NLS imaging, and colorectal cancer screening using virtual multivariable NLS imaging combined with CT or MRI (as an alternative to colonoscopy). A key outcome of these advancements is the early diagnosis of lung cancer cases.
Modern diagnostic procedures for lung cancer screening are increasingly based on virtual spiral NLS technology. Compared to conventional radiography and fluorography, the primary advantage of this technique is its superior resolution. Virtual NLS enables the effective detection of lung tissue nodules as small as 0.5–0.7 mm. Most major studies indicate that virtual NLS can detect pulmonary lesions in 10–12% of high-risk individuals, with 0.5–1.5% of these cases being bronchial carcinoma. More than 80% of these tumors go undetected by standard radiography, which has a resolution limit of 3–5 mm. NLS can detect cancer at stage I in 80–95% of patients.
The primary limitations to the widespread implementation of bronchial carcinoma screening are the high rate of false-positive results and the lack of conclusive evidence demonstrating a reduction in mortality among the screened group compared to other groups or the general population.